Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5-HT3 Antagonist, in Cancer Patients Treated with Cisplatin

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1

“…Similar to previous investigations [3][4][5], acute, reversible, and asymptomatic changes in PR interval and QRS duration were observed after therapeutic doses of dolasetron mesylate, with no apparent differences based on route of administration. These electrocardiographic changes are consistent with those observed following administration of other 5-HT 3 receptor antagonists [22,23].…”

“…Dolasetron, a new addition to the 5-HT 3 receptor antagonist class, has been shown to be an effective antiemetic in patients receiving highly emetogenic chemotherapy [3][4][5]. The disposition of dolasetron has been partially characterized and described in small numbers of healthy subjects, as illustrated in Figure 1 [6][7][8][9].…”

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

“…As in previous dolasetron studies [14,15,23,30,31] and other 5-HT 3 antagonists trials [32,33], tiredness and headache were the most commonly reported adverse events. As in previous studies with 5-HT 3 receptor antagonists [3,13,15,22,23,31,32,34], we also noted asymptomatic changes in ECG intervals.…”

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2

“…One difference in the adverse event profile among 5-HT 3 receptor antagonists appears to be the frequency of constipation. Constipation is a common adverse event reported with ondansetron [13] and granisetron [15,16], but occurs less frequently with dolasetron [12,17,18]. Neither constipation nor diarrhea occurred following single or multiple doses of oral dolasetron in this investigation.…”